Five-Year Experience of Second-Generation Cryoballoon Ablation for Paroxysmal Atrial Fibrillation from a Tertiary Cardiac Care Center of Pakistan: A Retrospective Chart Review

Authors

  • Muhammad Sarim Ansari National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan
  • Ghazala Irfan National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan
  • Zubair Mumtaz National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan
  • Faisal Qadir National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan
  • Maqsood Alam National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan
  • Sajid Ali Shaikh National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan
  • Abdul Mueed National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan

DOI:

https://doi.org/10.47144/phj.v56i2.2514

Abstract

Objectives: The study aimed at assessing the outcome of pulmonary vein isolation (PVI) using second-generation cryoballoon, Arctic Front Advance, Medtronic (CB-Adv) as a rhythm control strategy for drug-resistant paroxysmal atrial fibrillation (PAF) in a cardiac tertiary care center of Pakistan.

Methodology: Fifty patients had PVI with CB-Adv for symptomatic drug-resistant PAF at the National Institute of Cardiovascular Diseases, Karachi, Pakistan, during 2017-2022. Patients were followed-up in the clinic on the 1st, 3rd, and 6th month after the ablation. Twenty-four hours of Holter monitoring of electrocardiogram was obtained on each visit. We conducted a retrospective chart review after approval from the ethical review committee. We collected all the patients' demographic and clinical data, procedural results, and reports of Holter monitoring. The primary outcome was successful PVI and freedom from atrial tachyarrhythmia (Ata) on a 6-month follow-up.

Results: We enrolled all 50 patients (34 male, 68%; mean age 55.14 ± 7.94 years) treated with PVI using CB-Adv. The mean duration of symptoms was 30.28 ± 13.48 months. PVI with CB-Adv was found to be curative in 49 patients (98%). Following the procedure, pericardial effusion was found in one patient (2%), whereas one patient (2%) had a retroperitoneal hematoma. On a six-month follow-up, only one patient (2%) had a recurrence of Ata, which was PAF.

Conclusion: Our experience of PVI with CB-Adv has shown a high success rate of the procedure for rhythm control in patients who have PAF, which is resistant to antiarrhythmic drugs (AADs).

Downloads

Download data is not yet available.

Downloads

Published

2023-06-29

How to Cite

1.
Ansari MS, Irfan G, Mumtaz Z, Qadir F, Alam M, Shaikh SA, Mueed A. Five-Year Experience of Second-Generation Cryoballoon Ablation for Paroxysmal Atrial Fibrillation from a Tertiary Cardiac Care Center of Pakistan: A Retrospective Chart Review. Pak Heart J [Internet]. 2023Jun.29 [cited 2024Jul.12];56(2):146-51. Available from: https://www.pakheartjournal.com/index.php/pk/article/view/2514

Issue

Section

Original Article